- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
BTI's Magnes II cleared in Japan
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego announced last month that its Japanese distributor,Sumitomo Metal Industries, has received clearance from the JapaneseMinistry of Health to market its Magnes II MSI system. The
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego announced last month that its Japanese distributor,Sumitomo Metal Industries, has received clearance from the JapaneseMinistry of Health to market its Magnes II MSI system. The actionmeans that Magnes II can be marketed in other Asian countriesthat recognize the Japanese agency's approval.
On the downside, BTI last month posted lower financial numbersfor its third quarter (end-June). Revenues for the quarter were$1.8 million, down 27% compared to $2.5 million in the same periodin 1994. The firm's net loss was $2.2 million, which includeda non-recurring charge of $595,000, compared to a net loss of$1.4 million in the third quarter of 1994.
The company's backlog is at $11.3 million, however, which isthe highest level in BTI's history. It was aided by an order inAugust for a Magnes Whole Head system, a next-generation MSI scannerintroduced at last year's Radiological Society of North Americameeting (SCAN 3/15/95). That system will be shipped to the Institutefor Research in Neurosciences and Psychiatry in Rouffach, France.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
